<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;ff=20230805042344&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.17.9.post6+86293ac&amp;ff=20230805042344&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sat, 05 Aug 2023 08:23:45 +0000</lastbuilddate>
<pubDate>Fri, 04 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Coronary Plaque Sampling Reveals Molecular Insights Into Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37539553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 4. doi: 10.1161/CIRCRESAHA.123.323022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37539553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37539553</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323022>10.1161/CIRCRESAHA.123.323022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37539553</guid>
<pubDate>Fri, 04 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael E Widlansky</dc:creator>
<dc:creator>Yong Liu</dc:creator>
<dc:creator>Shakirah Tumusiime</dc:creator>
<dc:creator>Benjamin Hofeld</dc:creator>
<dc:creator>Nabeel Khan</dc:creator>
<dc:creator>Michael Aljadah</dc:creator>
<dc:creator>Jingli Wang</dc:creator>
<dc:creator>Amberly Anger</dc:creator>
<dc:creator>Qiongzi Qiu</dc:creator>
<dc:creator>Bhavika Therani</dc:creator>
<dc:creator>Pengyuan Liu</dc:creator>
<dc:creator>Mingyu Liang</dc:creator>
<dc:date>2023-08-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Coronary Plaque Sampling Reveals Molecular Insights Into Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37539553</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323022</dc:identifier>
</item>
<item>
<title>Chromosome-level organization of the regulatory genome in the Drosophila nervous system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37536338/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>Previous studies have identified topologically associating domains (TADs) as basic units of genome organization. We present evidence of a previously unreported level of genome folding, where distant TAD pairs, megabases apart, interact to form meta-domains. Within meta-domains, gene promoters and structural intergenic elements present in distant TADs are specifically paired. The associated genes encode neuronal determinants, including those engaged in axonal guidance and adhesion. These...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Jul 25:S0092-8674(23)00741-9. doi: 10.1016/j.cell.2023.07.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Previous studies have identified topologically associating domains (TADs) as basic units of genome organization. We present evidence of a previously unreported level of genome folding, where distant TAD pairs, megabases apart, interact to form meta-domains. Within meta-domains, gene promoters and structural intergenic elements present in distant TADs are specifically paired. The associated genes encode neuronal determinants, including those engaged in axonal guidance and adhesion. These long-range associations occur in a large fraction of neurons but support transcription in only a subset of neurons. Meta-domains are formed by diverse transcription factors that are able to pair over long and flexible distances. We present evidence that two such factors, GAF and CTCF, play direct roles in this process. The relative simplicity of higher-order meta-domain interactions in Drosophila, compared with those previously described in mammals, allowed the demonstration that genomes can fold into highly specialized cell-type-specific scaffolds that enable megabase-scale regulatory associations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37536338/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37536338</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.008>10.1016/j.cell.2023.07.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37536338</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Giriram Mohana</dc:creator>
<dc:creator>Julien Dorier</dc:creator>
<dc:creator>Xiao Li</dc:creator>
<dc:creator>Marion Mouginot</dc:creator>
<dc:creator>Rebecca C Smith</dc:creator>
<dc:creator>Héléna Malek</dc:creator>
<dc:creator>Marion Leleu</dc:creator>
<dc:creator>Daniel Rodriguez</dc:creator>
<dc:creator>Jenisha Khadka</dc:creator>
<dc:creator>Patrycja Rosa</dc:creator>
<dc:creator>Pascal Cousin</dc:creator>
<dc:creator>Christian Iseli</dc:creator>
<dc:creator>Simon Restrepo</dc:creator>
<dc:creator>Nicolas Guex</dc:creator>
<dc:creator>Brian D McCabe</dc:creator>
<dc:creator>Aleksander Jankowski</dc:creator>
<dc:creator>Michael S Levine</dc:creator>
<dc:creator>Maria Cristina Gambetta</dc:creator>
<dc:date>2023-08-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Chromosome-level organization of the regulatory genome in the Drosophila nervous system</dc:title>
<dc:identifier>pmid:37536338</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.008</dc:identifier>
</item>
<item>
<title>Connecting the Dots From GWAS to Function in Atrial Fibrillation for &lt;em>;ZFHX3&lt;/em>;</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37535755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 4;133(4):330-332. doi: 10.1161/CIRCRESAHA.123.323281. Epub 2023 Aug 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37535755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37535755</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323281>10.1161/CIRCRESAHA.123.323281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37535755</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Sojin Y Wass</dc:creator>
<dc:creator>Jonathan D Smith</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:date>2023-08-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Connecting the Dots From GWAS to Function in Atrial Fibrillation for &lt;em>;ZFHX3&lt;/em>;</dc:title>
<dc:identifier>pmid:37535755</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323281</dc:identifier>
</item>
<item>
<title>Mechanisms of Lymphatic Endothelial Cell Junction Transformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37535754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 4;133(4):350-352. doi: 10.1161/CIRCRESAHA.123.323210. Epub 2023 Aug 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37535754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37535754</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323210>10.1161/CIRCRESAHA.123.323210</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37535754</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jianyong Zhong</dc:creator>
<dc:creator>Elaine L Shelton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:creator>Valentina Kon</dc:creator>
<dc:date>2023-08-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Mechanisms of Lymphatic Endothelial Cell Junction Transformations</dc:title>
<dc:identifier>pmid:37535754</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323210</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37535753/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Aug 4;133(4):296-297. doi: 10.1161/RES.0000000000000627. Epub 2023 Aug 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37535753/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37535753</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000627>10.1161/RES.0000000000000627</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37535753</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:date>2023-08-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37535753</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000627</dc:identifier>
</item>
<item>
<title>Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37534453/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with HFpEF, treatment with dapagliflozin reduces resting and exercise PCWP, along with the favorable effects on plasma volume and body weight. These findings provide new insight into the hemodynamic mechanisms of benefit with sodium-glucose cotransporter-2 inhibitors in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a single-center, double-blinded, randomized, placebo-controlled trial testing the effects of 10 mg of dapagliflozin once daily in patients with HFpEF. Patients with New York Heart Association class II or III heart failure, ejection fraction ≥50%, and elevated PCWP during exercise were recruited. Cardiac hemodynamics were measured at rest and during exercise using high-fidelity micromanometers at baseline and after 24 weeks of treatment. The primary end point was a change from baseline in rest and peak exercise PCWPs that incorporated both measurements, and was compared using a mixed-model likelihood ratio test. Key secondary end points included body weight and directly measured blood and plasma volumes. Expired gas analysis was performed evaluate oxygen transport in tandem with arterial lactate sampling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 38 patients completing baseline assessments (median age 68 years; 66% women; 71% obese), 37 completed the trial. Treatment with dapagliflozin resulted in reduction in the primary end point of change in PCWP at rest and during exercise at 24 weeks relative to treatment with placebo (likelihood ratio test for overall changes in PCWP; <i>P</i>&lt;0.001), with lower PCWP at rest (estimated treatment difference [ETD], -3.5 mm Hg [95% CI, -6.6 to -0.4]; <i>P</i>=0.029) and maximal exercise (ETD, -5.7 mm Hg [95% CI, -10.8 to -0.7]; <i>P</i>=0.027). Body weight was reduced with dapagliflozin (ETD, -3.5 kg [95% CI, -5.9 to -1.1]; <i>P</i>=0.006), as was plasma volume (ETD, -285 mL [95% CI, -510 to -60]; <i>P</i>=0.014), but there was no significant effect on red blood cell volume. There were no differences in oxygen consumption at 20-W or peak exercise, but dapagliflozin decreased arterial lactate at 20 W (-0.70 ± 0.77 versus 0.37 ± 1.29 mM; <i>P</i>=0.006).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF, treatment with dapagliflozin reduces resting and exercise PCWP, along with the favorable effects on plasma volume and body weight. These findings provide new insight into the hemodynamic mechanisms of benefit with sodium-glucose cotransporter-2 inhibitors in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT04730947.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37534453/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37534453</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065134>10.1161/CIRCULATIONAHA.123.065134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37534453</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Yogesh N V Reddy</dc:creator>
<dc:creator>Amanda Braun</dc:creator>
<dc:creator>Hidemi Sorimachi</dc:creator>
<dc:creator>Massar Omar</dc:creator>
<dc:creator>Dejana Popovic</dc:creator>
<dc:creator>Alessio Alogna</dc:creator>
<dc:creator>Michael D Jensen</dc:creator>
<dc:creator>Rickey Carter</dc:creator>
<dc:date>2023-08-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial</dc:title>
<dc:identifier>pmid:37534453</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065134</dc:identifier>
</item>
<item>
<title>Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37534410/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 3:ehad440. doi: 10.1093/eurheartj/ehad440. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37534410/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37534410</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad440>10.1093/eurheartj/ehad440</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37534410</guid>
<pubDate>Thu, 03 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramesh Nadarajah</dc:creator>
<dc:creator>Yoko M Nakao</dc:creator>
<dc:creator>Jianhua Wu</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:date>2023-08-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Using routinely collected health record data for the earlier detection of heart failure with preserved ejection fraction: FIND-HFpEF</dc:title>
<dc:identifier>pmid:37534410</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad440</dc:identifier>
</item>
<item>
<title>Novel macrophage targets for the treatment of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Aug 2. doi: 10.1038/s41569-023-00918-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532948</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00918-7>10.1038/s41569-023-00918-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532948</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel macrophage targets for the treatment of atrial fibrillation</dc:title>
<dc:identifier>pmid:37532948</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00918-7</dc:identifier>
</item>
<item>
<title>REPLY: Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e47-e48. doi: 10.1016/j.jacc.2023.06.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532430</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.004>10.1016/j.jacc.2023.06.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532430</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Vinay Badhwar</dc:creator>
<dc:creator>J Hunter Mehaffey</dc:creator>
<dc:creator>Robert H Habib</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation</dc:title>
<dc:identifier>pmid:37532430</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.004</dc:identifier>
</item>
<item>
<title>Surgical Risk Scores in Mitral Valve Surgery and the Danger of Channeling Bias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e45. doi: 10.1016/j.jacc.2023.04.058.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532429</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.058>10.1016/j.jacc.2023.04.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532429</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jules R Olsthoorn</dc:creator>
<dc:creator>Niels Verberkmoes</dc:creator>
<dc:creator>Peyman Sardari Nia</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Surgical Risk Scores in Mitral Valve Surgery and the Danger of Channeling Bias</dc:title>
<dc:identifier>pmid:37532429</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.058</dc:identifier>
</item>
<item>
<title>Surgical Mitral Valve Repair: Excellent Outcomes, But for the Selected Few?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532428/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e43. doi: 10.1016/j.jacc.2023.02.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532428/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532428</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.02.054>10.1016/j.jacc.2023.02.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532428</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohamad Alkhouli</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Surgical Mitral Valve Repair: Excellent Outcomes, But for the Selected Few?</dc:title>
<dc:identifier>pmid:37532428</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.02.054</dc:identifier>
</item>
<item>
<title>Gender Disparity in Citations and Altmetric Attention Scores in High-Impact Cardiology Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):572-573. doi: 10.1016/j.jacc.2023.05.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532427</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.044>10.1016/j.jacc.2023.05.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532427</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Kristen N Brown</dc:creator>
<dc:creator>Ridhima Goel</dc:creator>
<dc:creator>Sana Soman</dc:creator>
<dc:creator>Essaq Khan</dc:creator>
<dc:creator>Lina Ya'Qoub</dc:creator>
<dc:creator>Vinicius Calsavara</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Poonam Velagapudi</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Disparity in Citations and Altmetric Attention Scores in High-Impact Cardiology Journals</dc:title>
<dc:identifier>pmid:37532427</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.044</dc:identifier>
</item>
<item>
<title>Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapidly evolving evidence-base, as a number of recent clinical trials have demonstrated multiple therapies to be safe and efficacious in this high-risk population. Herein, we propose a framework for treating worsening HF with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapidly evolving evidence-base, as a number of recent clinical trials have demonstrated multiple therapies to be safe and efficacious in this high-risk population. Herein, we propose a framework for treating worsening HF with reduced ejection fraction with the sense of urgency it deserves. This includes treating congestion; managing precipitants; and establishing a foundation of rapid-sequence, simultaneous, and/or in-hospital initiation of quadruple medical therapy for HF with reduced ejection fraction, with the top priority being at least low doses of all 4 medications. Moreover, to maximally reduce residual clinical risk, we further propose consideration of upfront simultaneous use of vericiguat (ie, quintuple medical therapy) and administration of intravenous iron for those who are iron deficient.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532426</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.057>10.1016/j.jacc.2023.04.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532426</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Jasper J Brugts</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Burkert Pieske</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Natalie Skopicki</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3</dc:title>
<dc:identifier>pmid:37532426</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.057</dc:identifier>
</item>
<item>
<title>Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>Heart failure (HF) is a leading cause of death and disability in older adults. Despite decades of high-quality evidence to support their use, guideline-directed medical therapies (GDMTs) that reduce death and disease burden in HF have been suboptimally implemented. Approaches to closing care gaps have focused largely on strategies proven to be ineffective, whilst effective interventions shown to improve GDMT uptake have not been instituted. This review synthesizes implementation interventions...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):544-558. doi: 10.1016/j.jacc.2023.05.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) is a leading cause of death and disability in older adults. Despite decades of high-quality evidence to support their use, guideline-directed medical therapies (GDMTs) that reduce death and disease burden in HF have been suboptimally implemented. Approaches to closing care gaps have focused largely on strategies proven to be ineffective, whilst effective interventions shown to improve GDMT uptake have not been instituted. This review synthesizes implementation interventions that increase the uptake of GDMT, discusses barriers and facilitators of implementation, summarizes conceptual frameworks in implementation science that could improve knowledge uptake, and offers suggestions for trial design that could better facilitate end-of-trial implementation. We propose an evidence-to-care conceptual model that could foster the simultaneous generation of evidence and long-term implementation. By adopting principles of implementation science, policymakers, researchers, and clinicians can help reduce the burden of HF on patients and health care systems worldwide.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532425</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.050>10.1016/j.jacc.2023.05.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532425</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohamed B Jalloh</dc:creator>
<dc:creator>Tauben Averbuch</dc:creator>
<dc:creator>Prashanth Kulkarni</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3</dc:title>
<dc:identifier>pmid:37532425</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.050</dc:identifier>
</item>
<item>
<title>Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532424/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>Despite the availability of lifesaving guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), there remain major gaps in utilization of these therapies among eligible patients. Simultaneous with these gaps in quality of care, HFrEF continues as a leading cause of death and hospitalization with associated clinical risk far exceeding most other cardiovascular and noncardiovascular conditions. In the context of this urgent need to improve provision of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):529-543. doi: 10.1016/j.jacc.2023.03.430.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite the availability of lifesaving guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), there remain major gaps in utilization of these therapies among eligible patients. Simultaneous with these gaps in quality of care, HFrEF continues as a leading cause of death and hospitalization with associated clinical risk far exceeding most other cardiovascular and noncardiovascular conditions. In the context of this urgent need to improve provision of appropriate therapy, multiple lines of evidence support various implementation strategies. Such strategies include in-hospital initiation of GDMT, simultaneous or rapid sequence initiation of GDMT, participation in quality improvement registries to assess site performance and provide feedback, multidisciplinary titration clinics, virtual consult teams, reduction of cost-sharing, remote algorithm-based medication optimization, electronic health record-based interventions, and direct-to-patient educational initiatives. This review describes and contextualizes the evidence surrounding each of these potential avenues for improving use of foundational GDMTs for patients with HFrEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532424/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532424</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.03.430>10.1016/j.jacc.2023.03.430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532424</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Harsh Patolia</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3</dc:title>
<dc:identifier>pmid:37532424</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.03.430</dc:identifier>
</item>
<item>
<title>GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):526-528. doi: 10.1016/j.jacc.2023.06.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532423</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.005>10.1016/j.jacc.2023.06.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532423</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Vanita R Aroda</dc:creator>
<dc:creator>Liana K Billings</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection</dc:title>
<dc:identifier>pmid:37532423</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.005</dc:identifier>
</item>
<item>
<title>GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):517-525. doi: 10.1016/j.jacc.2023.05.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the effects of GLP-1 RAs on cardiovascular outcomes in patients with T2D treated with or without SGLT2 inhibitors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Post hoc analysis of Harmony Outcomes (Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease) evaluating the effect of albiglutide in T2D with cardiovascular disease by background SGLT2 inhibitor use. Additionally, a trial-level meta-analysis of Harmony Outcomes and AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes), which evaluated T2D with cardiovascular or renal disease, was performed, combining the treatment effect estimates according to SGLT2 inhibitor use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 9,462 participants in Harmony Outcomes, 575 (6.1%) were treated with SGLT2 inhibitors at baseline. The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). The effect of albiglutide on secondary outcomes and adverse events was not modified by SGLT2 inhibitors. A meta-analysis of Harmony Outcomes and AMPLITUDE-O included 13,538 patients, of whom 1,193 (8.8%) used SGLT2 inhibitors. Compared to placebo, GLP1-RAs reduced major adverse cardiovascular events without effect modification by SGLT2 inhibitor use (HR: 0.77; 95% CI: 0.68-0.87 without SGLT2 inhibitors; and HR: 0.78; 95% CI: 0.49-1.24 with SGLT2 inhibitors) (P for interaction = 0.95) and reduced heart failure hospitalization (HR: 0.72; 95% CI: 0.55-0.92 vs HR: 0.34; 95% CI: 0.12-0.96) (P for interaction = 0.18).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532422</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.048>10.1016/j.jacc.2023.05.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532422</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>João Sérgio Neves</dc:creator>
<dc:creator>Marta Borges-Canha</dc:creator>
<dc:creator>Francisco Vasques-Nóvoa</dc:creator>
<dc:creator>Jennifer B Green</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Davide Carvalho</dc:creator>
<dc:creator>Adelino Leite-Moreira</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Stefano Del Prato</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes</dc:title>
<dc:identifier>pmid:37532422</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.048</dc:identifier>
</item>
<item>
<title>Ebstein Anomaly: More Than Just a Tricuspid Valve Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):514-516. doi: 10.1016/j.jacc.2023.05.041.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532421</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.041>10.1016/j.jacc.2023.05.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532421</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Anne M Valente</dc:creator>
<dc:creator>David M Harrild</dc:creator>
<dc:creator>Rebecca S Beroukhim</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ebstein Anomaly: More Than Just a Tricuspid Valve Issue</dc:title>
<dc:identifier>pmid:37532421</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.041</dc:identifier>
</item>
<item>
<title>Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients With Ebstein Anomaly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532420/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These data support the use of RVGLS for risk stratification in Ebstein anomaly, and further studies are required to assess how interventions may affect different patients according to risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):503-513. doi: 10.1016/j.jacc.2023.05.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There are limited data on the prognostic role of right ventricular global longitudinal strain (RVGLS) in patients with Ebstein anomaly.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the relationship between RVGLS and mortality and to compare prognostic performance of RVGLS with conventional echocardiographic indices of right ventricular (RV) systolic function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study identified adults with Ebstein anomaly with echocardiographic assessment of RV systolic function (RVGLS, RV fractional area change [RVFAC], RV tissue Doppler systolic velocity [RV s'], and tricuspid annular plane systolic excursion [TAPSE]) from 2003 to 2020. For ease of presentation, RVGLS was modeled as absolute values (ie, without the negative sign).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 620 patients (median age 37 years; men 261 [42%]), the mean absolute RVGLS, RVFAC, RV s', and TAPSE were 18% ± 5%, 32% ± 9%, 14 ± 6 cm/s, and 22 ± 8 mm, respectively. There were correlations between absolute RVGLS and RVFAC (r = 0.71; P &lt; 0.001), between absolute RVGLS and RV s' (r = 0.41; P = 0.03), and between absolute RVGLS and TAPSE (r = 0.44; P = 0.002). Of 620 patients, 47 (8%) died during follow-up, and 34 of these deaths were cardiovascular. Absolute RVGLS was independently associated with all-cause mortality (adjusted HR: 0.94; 95% CI: 0.92-0.96 per unit increase) and cardiovascular mortality (adjusted HR: 0.92; 95% CI: 0.90-0.94 per unit increase). Absolute RVGLS had superior prognostic power (ie, ability to predict mortality) as compared with RVFAC, RV s', or TAPSE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data support the use of RVGLS for risk stratification in Ebstein anomaly, and further studies are required to assess how interventions may affect different patients according to risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532420/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532420</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.045>10.1016/j.jacc.2023.05.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532420</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Egbe</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:creator>C Charles Jain</dc:creator>
<dc:creator>Kartik Andi</dc:creator>
<dc:creator>Omar Abozied</dc:creator>
<dc:creator>Ahmed K Younis</dc:creator>
<dc:creator>Sriharsha Kandlakunta</dc:creator>
<dc:creator>Abdalla A Salama</dc:creator>
<dc:creator>Elizabeth H Stephens</dc:creator>
<dc:creator>Heidi M Connolly</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients With Ebstein Anomaly</dc:title>
<dc:identifier>pmid:37532420</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.045</dc:identifier>
</item>
<item>
<title>Right Heart Dysfunction in HFpEF: More Complex and More Common Than We Thought</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532419/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):500-502. doi: 10.1016/j.jacc.2023.05.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532419/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532419</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.049>10.1016/j.jacc.2023.05.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532419</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julia Grapsa</dc:creator>
<dc:creator>Sean P Pinney</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Heart Dysfunction in HFpEF: More Complex and More Common Than We Thought</dc:title>
<dc:identifier>pmid:37532419</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.049</dc:identifier>
</item>
<item>
<title>The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230805042344&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):486-488. doi: 10.1016/j.jacc.2023.05.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230805042344&v=2.17.9.post6+86293ac">37532418</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.047>10.1016/j.jacc.2023.05.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532418</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes</dc:title>
<dc:identifier>pmid:37532418</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.047</dc:identifier>
</item>





























</channel>
</rss>